China Regulatory Express: Biosecurity Law, Export Controls And The Life Science Sector
Stiffer Fines For Violators
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
You may also be interested in...
China Regulatory Express: Online Rx Sales Proposal To Propel Drug Sales?
In its most recent regulatory reforms, China is proposing to allow online sales of prescription drugs, a major step forward that could boost struggling retail pharmacies and further propel medicine e-commerce.
China Roundup: Rare Disease Approvals, Local mRNA Shots, CEO Visits
AstraZeneca and CANbridge obtain new approvals for their rare disease drugs in China, where a new domestic mRNA vaccine is also being made available amid a new wave of COVID infections. Meanwhile, the CEOs of pharma and other companies pay visits, showing China remains high on their list of global priorities.
Falling At The Start Line: Chinese Firms Face Multiple Commercial Challenges Beyond Price, Coverage
Sales of a global first-in-class dermatology drug that gained its first approval in China are falling well behind those of its overseas counterpart. In this case study, Scrip takes a deep dive into the multiple underlying factors determining success in the world's second-largest pharma market beyond pricing and reimbursement coverage, including complex hospital entry, dual channels and competition considerations.